Abstract 1232P
Background
Randomized controlled trials (RCTs) showed survival improvement with neoadjuvant/perioperative ICI + CT in early NSCLC. However, interpretation of the results can be affected by a variable level of uncertainty due to censoring imbalance and vulnerability of statistical conclusions.
Methods
PubMed, Embase and Cochrane were searched until April 2024 for RCTs comparing neoadjuvant/perioperative ICI + CT with neoadjuvant CT in patients with early-stage NSCLC. Individual Patient Data (IPD) curves and the corresponding hazard ratios (HR) were reconstructed from published EFS Kaplan-Meier data from each trial and treatment arm by using an IPD software. Reverse HR (R-HR) was obtained by flipping the status of time-dependent outcome for individual patients (reverse Kaplan Meier method) and were used to estimate censoring imbalance. SIFI was determined by iteratively transferring the best survivors from the experimental arm to the control arm until p≥0.05; conversely, negative SIFI was calculated until p<0.05.
Results
Eight RCTs (n=3387) were included. R-HR analysis showed a trend in increased censoring imbalance in the experimental arm in 1 RCT (NADIM II) and in the control arm in 2 RCTs (NeoTORCH, TD-FOREKNOW), in 1 RCT (RATIONALE-315) censoring imbalance was significantly higher in the control arm (R-HR 1.30; 95% CI 1.02-1.65). Median SIFI was 12 (IQR, 4.25 - 20.25), with absolute weighted SIFI ≤ 2% in 3 RCTs (NADIM II, AEGEAN, Checkmate 816), suggesting a potential vulnerability affecting the significance of results. Table: 1232P
| Study name | N | IPD-HR | R-HR (control vs experimental) | SIFI (%) | Median FUP months (range, if specified) |
| AEGEAN | 740 | 0.70 (0.54 - 0.91) | 0.96 (0.80 - 1.15) | 9 (1) | 11.7 |
| NADIM II | 86 | 0.43 (0.21 - 0.86) | 0.51 (0.23 - 1.13) | 2 (2) | 26.1 (17.4 - 30.9) |
| CheckMate 816 | 358 | 0.66 (0.48-0.91) | 1.06 (0.80 - 1.41) | 5 (1) | 41.4 |
| NeoTORCH | 404 | 0.39 (0.28 - 0.54) | 1.12 (0.86 - 1.47) | 33 (8) | 18.3 |
| KEYNOTE 671 | 797 | 0.57 (0.46 - 0.70) | 0.99 (0.81 - 1.19) | 37 (5) | 25.2 (7.5 - 50.6) |
| CheckMate 77T | 461 | 0.58 (0.44 - 0.78) | 1 (0.78 - 1.28) | 15 (3) | 25.4 (15.7 - 44.2) |
| TD-FOREKNOW | 88 | 0.53 (0.21 - 1.30) | 1.33 (0.81 - 2.19) | -4 (5) | 14.1 (9.2 - 20.9) |
| RATIONALE-315 | 453 | 0.56 (0.40 - 0.79) | 1.30 (1.02 - 1.65) | 16 (4) | 22.0 |
Conclusions
Significant censoring imbalance in the control arm and high survival fragility were reported in 1 and 3 RCTs, respectively, suggesting that informative censoring and survival vulnerability are useful tools to ensure a reliable interpretation of data.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1220P - A phase III randomized trial investigating preventive effects of perioperative landiolol, a selective beta1 blocker, on the reduction of recurrence of completely resected NSCLC
Presenter: Yasuhiro Hida
Session: Poster session 04
1221P - Stereotactic ablative radiotherapy in combination with nivolumab for early stage operable non-small cell lung cancer: A phase II study
Presenter: Gustavo Schvartsman
Session: Poster session 04
1222P - Predicting pathological complete response to neoadjuvant chemoimmunotherapy in resected NSCLC with radiomic signatures
Presenter: Mohammadhadi Khorrami
Session: Poster session 04
Resources:
Abstract
1223P - Sex specific efficacy and safety outcomes in operable stage III non-small cell lung cancer (NSCLC): Pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14
Presenter: Lorenz Frehner
Session: Poster session 04
1224P - Evaluation of safety and feasibility of adjuvant chemotherapy in elderly patients with primary non-small cell lung cancer
Presenter: Alice MOGENET
Session: Poster session 04
1225P - Perioperative serplulimab and chemotherapy in patients with resectable squamous non-small cell lung cancer: An open-label, single-arm, phase II trial
Presenter: Haiquan Chen
Session: Poster session 04
1226P - Predictive value of circulating tumor DNA (ctDNA) before and shortly after curative treatment in early stage non-small cell lung cancer (NSCLC), and exploration of (pre-)analytical factors
Presenter: Michel van den Heuvel
Session: Poster session 04
1227P - Update on the analysis of operability parameter changes in neoadjuvant treatment with chemotherapy and anti-PD-1/PD-L1
Presenter: Maria Sereno
Session: Poster session 04
1228P - Association between air pollution and frequency of driver mutation among a Hispanic population with lung cancer
Presenter: Mateo Tamayo
Session: Poster session 04
Resources:
Abstract
1229P - Precision patient selection for postoperative therapy in resectable NSCLC: A comprehensive postoperative-risk model incorporating genetic and histological features
Presenter: Yuanzi Ye
Session: Poster session 04